Abstract
A series of substituted p-aminophenethylamines and some related compounds were examined with regards to the inhibition of monoamine oxidase (MAO) in vivo inside and outside 5-hydroxytryptaminergic neurones in the rat hypothalamus. This was recorded as the protection against the irreversible inhibition of MAO produced by phenelzine by determining the remaining deaminating activity in the absence and presence of citalopram using a low (0.1 microM) concentration of [14C]-5-hydroxytryptamine (5-HT) as substrate. Some of the phenethylamines were much more potent inside than outside the 5-hydroxytryptaminergic neurones. This neuronal selectivity was antagonized by pretreatment of the rats with norzimeldine, a 5-HT uptake inhibitor, which indicates that these compounds are accumulated in the 5-HT nerve terminals by the 5-HT pump. Selectivity was obtained for compounds with dimethyl, monomethyl or unsubstituted p-amino groups. An isopropyl group appears to substitute for the dimethylamino group but with considerably lower potency. Compounds with 2-substitution showed selectivity for aminergic neurones and this effect decreased with increased size of the substituent. The 2,6-dichloro derivative FLA 365 had, however, no neuronal selective action but was a potent MAO inhibitor. Substitutions in the 3- and 5-positions decreased both potency and selectivity. Prolongation of the side chain with one methylene group abolished the preference for the MAO in 5-hydroxytryptaminergic neurones although the MAO inhibitory potency remained. The selectivity disappeared by increasing the alpha-substituent to an ethyl group but remained for the alpha,alpha-dimethyl substituted derivatives. It is concluded that compounds which are (1) transported by the 5-HT pump and (2) potent reversible MAO-A inhibitors produce pronounced inhibition of MAO in 5-hydroxytryptaminergic neurones.
Full text
PDF
Selected References
These references are in PubMed. This may not be the complete list of references from this article.
- Ask A. L., Fagervall I., Ross S. B. Evidence for a selective inhibition by FLA 336(+) of the monoamine oxidase in serotonergic neurones in the rat brain. Acta Pharmacol Toxicol (Copenh) 1982 Oct;51(4):395–396. doi: 10.1111/j.1600-0773.1982.tb01042.x. [DOI] [PubMed] [Google Scholar]
- Ask A. L., Fagervall I., Ross S. B. Selective inhibition of monoamine oxidase in monoaminergic neurons in the rat brain. Naunyn Schmiedebergs Arch Pharmacol. 1983 Sep;324(2):79–87. doi: 10.1007/BF00497011. [DOI] [PubMed] [Google Scholar]
- Ask A. L., Hellström W., Norrman S., Ogren S. O., Ross S. B. Selective inhibition of the A form of monoamine oxidase by 4-dimethylamino-alpha-methylphenylalkylamine derivatives in the rat. Neuropharmacology. 1982 Apr;21(4):299–308. doi: 10.1016/0028-3908(82)90092-2. [DOI] [PubMed] [Google Scholar]
- Ask A. L., Högberg K., Schmidt L., Kiessling H., Ross S. B. (+)-4-Dimethylamino-2,alpha-dimethylphenethylamine (FLA 336(+)), a selective inhibitor of the A form of monoamine oxidase in the rat brain. Biochem Pharmacol. 1982 Apr 1;31(7):1401–1406. doi: 10.1016/0006-2952(82)90035-1. [DOI] [PubMed] [Google Scholar]
- Florvall L., Ask A. L., Ogren S. O., Ross S. B. Selective monoamine oxidase inhibitors. 1. Compounds related to 4-aminophenethylamine. J Med Chem. 1978 Jan;21(1):56–63. doi: 10.1021/jm00199a010. [DOI] [PubMed] [Google Scholar]
- Fowler C. J., Magnusson O., Ross S. B. Intra- and extraneuronal monoamine oxidase. Blood Vessels. 1984;21(3):126–131. doi: 10.1159/000158505. [DOI] [PubMed] [Google Scholar]
- Fowler C. J., Oreland L. Substrate- and stereoselective inhibitor of human brain monoamine oxidase by 4-dimethylamino-alpha, 2-dimethylphenethylamine (FLA 336). J Pharm Pharmacol. 1981 Jun;33(6):403–406. doi: 10.1111/j.2042-7158.1981.tb13819.x. [DOI] [PubMed] [Google Scholar]
- Green A. L., El Hait M. A. A new approach to the assessment of the potency of reversible monoamine oxidase inhibitors in vivo, and its application to (+)-amphetamine, p-methoxyamphetamine and harmaline. Biochem Pharmacol. 1980 Oct 15;29(20):2781–2789. doi: 10.1016/0006-2952(80)90012-x. [DOI] [PubMed] [Google Scholar]
- Hyttel J. Citalopram--pharmacological profile of a specific serotonin uptake inhibitor with antidepressant activity. Prog Neuropsychopharmacol Biol Psychiatry. 1982;6(3):277–295. doi: 10.1016/s0278-5846(82)80179-6. [DOI] [PubMed] [Google Scholar]
- Ross S. B., Ask A. L. Structural requirements for uptake into serotoninergic neurones. Acta Pharmacol Toxicol (Copenh) 1980 Apr;46(4):270–277. doi: 10.1111/j.1600-0773.1980.tb02453.x. [DOI] [PubMed] [Google Scholar]